Alivion

Alivion, headquartered in Switzerland, is a pioneering company founded in 2020, committed to enhancing quality of life through innovative health monitoring solutions. Leveraging over 15 years of research at ETH Zurich, Alivion specializes in precise biomarker analysis using cutting-edge technology to support a healthy lifestyle and mitigate health risks such as cardiovascular diseases and diabetes.

The company's flagship product, the Alivion SmartSelect™, offers near real-time, laboratory-level analysis that transforms how individuals monitor their health. This portable device employs sophisticated techniques like headspace gas chromatography to analyze breath and liquid samples for valuable dietary information.

Alivion has already made significant strides, evidenced by its receipt of several international awards for innovation. The company recently secured a seed investment on 01 July 2024 from SICTIC, further underscoring its potential and appeal. As an early-stage company with a robust technological foundation, Alivion presents a compelling opportunity for investors interested in health tech innovations.